(Q48759416)

15 February 2018

title

Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease? (English)

1 reference

15 February 2018

1 reference

1 reference

1 reference

15 February 2018

David Burn

1 reference

15 February 2018

Andrew John Lees

object named as

Andrew J Lees

1 reference

15 February 2018

Tammaryn Lashley

1 reference

15 February 2018

S.S. O'Sullivan

object named as

Sean S O'Sullivan

1 reference

15 February 2018

author name string

Helen Ling

1 reference

15 February 2018

Shirley Y Coleman

1 reference

15 February 2018

Yaroslau Compta

1 reference

15 February 2018

Tamas Revesz

1 reference

15 February 2018

language of work or name

English

0 references

publication date

13 October 2015

1 reference

15 February 2018

published in

Movement Disorders

1 reference

15 February 2018

volume

1 reference

15 February 2018

issue

1 reference

15 February 2018

page(s)

668-675

1 reference

15 February 2018

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

cites work

1 reference

Dementia and survival in Parkinson disease: a 12-year population study.

21 January 2018

1 reference

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

21 January 2018

1 reference

Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis.

21 January 2018

1 reference

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease

21 January 2018

1 reference

Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases

21 January 2018

1 reference

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

21 January 2018

1 reference

Neuropathologic substrates of Parkinson disease dementia

21 January 2018

1 reference

Neuropathology of dementia in a large cohort of patients with Parkinson's disease

21 January 2018

1 reference

Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

21 January 2018

1 reference

The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia

21 January 2018

1 reference

Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline

21 January 2018

1 reference

beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

New Class of Inhibitors of Amyloid-beta Fibril Formation. IMPLICATIONS FOR THE MECHANISM OF PATHOGENESIS IN ALZHEIMER'S DISEASE

21 January 2018

1 reference

Apomorphine treatment in Alzheimer mice promoting amyloid‐β degradation

21 January 2018

1 reference

Clinical diagnostic criteria for dementia associated with Parkinson's disease

21 January 2018

1 reference

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs

21 January 2018

1 reference

Does levodopa accelerate the pathologic process in Parkinson disease brain?

21 January 2018

1 reference

A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies

21 January 2018

1 reference

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

21 January 2018

1 reference

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

21 January 2018

1 reference

Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

21 January 2018

1 reference

What's wrong with Bonferroni adjustments

21 January 2018

1 reference

APOE ε4 increases risk for dementia in pure synucleinopathies

21 January 2018

1 reference

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

Amyloid beta-protein and the genetics of Alzheimer's disease

21 January 2018

1 reference

Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

Changes in motor subtype and risk for incident dementia in Parkinson's disease

21 January 2018

1 reference

Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies

21 January 2018

1 reference

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease

21 January 2018

1 reference

A clinico-pathological study of subtypes in Parkinson's disease

21 January 2018

1 reference

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.

21 January 2018

1 reference

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

21 January 2018

1 reference

Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.26422

1 reference

15 February 2018

1 reference

15 February 2018